Catalent lends its weight to an armed-antibody cancer candidate

Drug developer Catalent ($CTLT) is teaming up with biomarker outfit Minomic International to get a new prostate cancer treatment into the clinic, tapping its expertise in crafting targeted oncology treatments.

The drug is an antibody-drug conjugate, designed to home in on tumor cells by mimicking the body's natural defenses and deliver a cancer-killing payload while sparing healthy tissue. Under the agreement, Catalent will manufacture the antibody, called MIL-38, for a clinical study, and if the drug comes through in its first-in-human trial, the company will expand into larger-scale production.

The deal centers on Catalent's GPEx technology for biologics manufacturing, a speedy process the company touts as getting drug candidates into the clinic in about one-third the time it takes with traditional methods. Work on MIL-38 will take place at Catalent's biomanufacturing hub in Madison, WI, where the company recently invested about $20 million to roughly quadruple its capacity.

For Minomic, which is simultaneously working on a prostate cancer companion diagnostic, teaming up with Catalent provides a springboard for MIL-38 as it moves through early development, CEO Brad Walsh said.

"Early signs in the study are extremely encouraging," Walsh said in a statement. "... We are already close to bringing a new, noninvasive testing kit for prostate cancer to market using the same antibody target. Leveraging our existing technology to develop a therapeutic antibody in conjunction with Catalent is our ultimate aim."

As for Catalent, the New Jersey-headquartered company is in its early days as a public company after pulling off an $871.3 million IPO in July.

- read the statement

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.